Clinical Trial Update: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the combination of sintilimab with XELOX and bevacizumab as first-line therapy for RAS-mutant metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer Stage IV | Phase 3 | Status: ACTIVE_NOT_RECRUITING